Floatz logo

PEGASPARGASE

Down Syndrome

National Cancer Institute (NCI)protein_peptidePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

34 Active assets in the Down Syndrome cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BB
MERCAPTOPURINE ANHYDROUS
National Cancer Institute (NCI)
Phase 3BB
Cytosin-Arabinosid
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3BB
METHOTREXATE
National Cancer Institute (NCI)
Phase 3BB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
National Cancer Institute (NCI)
Phase 3BB

View all 36 →

Same molecule, other indications

PEGASPARGASE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
80 / 100
View asset →
Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →